You may find more results for this query on our sister sites: 360Dx and Precision Oncology News.
The firm expects to launch a 510(k)-cleared version of its Bladder EpiCheck recurrence assay early next year followed by an RUO early-stage lung cancer assay.
Swiss firm DKSH will market and sell Ubiquitome's Liberty16 PCR-based platform in Australia, New Zealand, and other countries in the region.
Children's Hospital Los Angeles used a SARS-CoV-2 sequencing panel to determine if patients had become infected from the same source as healthcare workers.
The German company's real-time PCR test is designed to detect SARS-CoV-2 genes E and RdRP in respiratory samples.
The UK Department of Health and Social Care has already ordered 10,000 RNA test cartridges from the company, which expects to obtain a CE-IVD mark for its test within weeks.
Fluidigm's Biomark HD microfluidic platform will enable more than 180,000 real-time PCR tests to be run over the next 90 days to potentially support COVID-19 screening.
Combining Ubiquitome's handheld PCR device and Oxford Nanopore's sequencer may enable a single person to screen 500 samples and obtain 24 whole genome sequences per day.
The researchers said their assay can be run in 30 to 45 minutes, with 95 percent positive predictive agreement and 100 percent negative predictive agreement.
The test, run on the BD Max system, allows hospitals to diagnose SARS-CoV-2 on site and receive results in less than three hours.
Bringing testing closer to patients could be helpful, provided enough tests and instruments can be manufactured and distributed.
New analyses indicate female researchers are publishing less during the coronavirus pandemic than male researchers, according to Nature News.
A study suggests people with the ApoE e4 genotype may be more likely to have severe COVID-19 than those with other genotypes, the Guardian says.
Direct-to-consumer genetic testing companies are searching for a genetic reason for why some people, but not others, become gravely ill with COVID-19, the Detroit Free Press reports.
In PNAS this week: forward genetics-base analysis of retinal development, interactions of T cell receptors with neoantigens in colorectal cancer, and more.